XML 109 R65.htm IDEA: XBRL DOCUMENT
v3.22.4

Financial assets and liabilities measured at fair value (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Fair Value Measurement [Abstract] |
Summary of Assets and Liabilities Measured at Fair Value | The table below shows the balance sheet amounts of assets and liabilities measured at fair value.
|  | 2022 | 2021 | 2020
|  | Level in the fair value hierarchy | Level in the fair value hierarchy | Level in the fair value hierarchy
(€ million) | Note | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3
Financial assets measured at fair value |  |  |  |  |  |  |  |  |  |
Quoted equity investments | D.7.1. | 387 |  | — |  | — |  | 396 |  | — |  | — |  | 439 |  | — |  | — |
Unquoted equity investments | D.7.1. | — |  | — |  | 549 |  | — |  | — |  | 427 |  | — |  | — |  | 149 |
Quoted debt securities | D.7.2. | 329 |  | — |  | — |  | 447 |  | — |  | — |  | 426 |  | — |  | — |
Unquoted debt securities not meeting the definition of equity instruments | D.7.3. | — |  | — |  | 115 |  | — |  | — |  | 78 |  | — |  | — |  | 63 |
Contingent consideration relating to divestments | D.7.3. | — |  | — |  | 303 |  | — |  | — |  | 378 |  | — |  | — |  | 483 |
Financial assets held to meet obligations under deferred compensation plans | D.7.3. and D.11. | 512 |  | — |  | — |  | 549 |  | — |  | — |  | 454 |  | — |  | — |
Non-current derivatives | D.7. | — |  | — |  | — |  | — |  | 3 |  | — |  | — |  | 24 |  | — |
Current derivatives | D.11. | — |  | 206 |  | — |  | — |  | 295 |  | — |  | — |  | 58 |  | — |
Mutual fund investments | D.13. | 9,537 |  | — |  | — |  | 5,057 |  | — |  | — |  | 8,703 |  | — |  | — |
Total financial assets measured at fair value |  | 10,765 |  | 206 |  | 967 |  | 6,449 |  | 298 |  | 883 |  | 10,022 |  | 82 |  | 695 |
Financial liabilities measured at fair value |  |  |  |  |  |  |  |  |  |
Bayer contingent purchase consideration arising from the acquisition of Genzyme | D.18. | — |  | — |  | 26 |  | — |  | — |  | 59 |  | — |  | — |  | 104 |
MSD contingent consideration (European vaccines business) | D.18. | — |  | — |  | 204 |  | — |  | — |  | 269 |  | — |  | — |  | 312 |
Shire contingent consideration arising from the acquisition of Translate Bio | D.18. | — |  | — |  | 380 |  | — |  | — |  | 354 |  | — |  | — |  | — |
Contingent consideration arising from acquisition of Amunix | D.18. | — |  | — |  | 165 |  | — |  | — |  | — |  | — |  | — |  | — |
Other contingent consideration arising from business combinations and acquisitions | D.18. | — |  | — |  | 4 |  | — |  | — |  | 32 |  | — |  | — |  | 189 |
Non-current derivatives | D.19. | — |  | 232 |  | — |  | — |  | 6 |  | — |  | — |  | 92 |  | — |
Current derivatives | D.19.5 | — |  | 94 |  | — |  | — |  | 79 |  | — |  | — |  | 205 |  | — |
Total financial liabilities measured at fair value |  | — |  | 326 |  | 779 |  | — |  | 85 |  | 714 |  | — |  | 297 |  | 605 |

X
- Definition Disclosure of fair value of financial assets and liabilities explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfFairValueOfFinancialAssetsAndLiabilitiesExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Measurement [Abstract] + References No definition available. + Details
Name: | sny_FairValueMeasurementAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration